Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-137499

Published: 2020

Journal Articles

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-136344

Published: 2020

Journal Articles

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139192

Published: 2020

Journal Articles

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

Rajat Bannerji, MDPhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Susan M. O'Brien, MD, Johannes Duell, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Jingjin Li, PhD, Dina M. Flink, PhD, Min Zhu, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Max S. Topp, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136659

Published: 2020

Journal Articles

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Francisco Cervantes, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andres Sirulnik, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S. Hunter, Richard S. Levy, Francesco Passamonti, Tiziano Barbui, Giovanni Barosi, Claire N. Harrison, Laurent Knoops, Heinz Gisslinger

Blood (2013) 122 (25): 4047–4053.

https://doi.org/10.1182/blood-2013-02-485888

Published: 2013

Includes: Supplemental data

Journal Articles

A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis

Alessandro M. Vannucchi, MD, Kantarjian Hagop, Jean-Jacques Kiladjian, MD, PhD, Jason Gotlib, MD, MS, Francisco Cervantes, MD, PhD, Ruben A. Mesa, MD, Giovanni Barosi, MD, Nicholas Sarlis, Wei Peng, PhD, Victor A. Sandor, MD, CM, Andres Sirulnik, MD, PhD, Abdel Hmissi, Viktoriya Stalbovskaya, PhD, Vikas Gupta, MD, FRCP, FRCPath, Claire N Harrison, DM, FRCP, FRCPath, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 2820.

https://doi.org/10.1182/blood.V122.21.2820.2820

Published: 2013

Journal Articles

A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)

Chul Won Jung, MD, PhD, Lee-Yung Shih, MD, Zhijian Xiao, MD, Jie Jin, MD, Hsin-An Hou, MD, Xin Du, MD, Ming-Chung Wang, MD, Seonyang Park, MD, PhD, Ki-Seong Eom, MD, PhD, Kenji Oritani, Shinichiro Okamoto, MD, PhD, Tetsuzo Tauchi, MD, Jin Seok Kim, MD, Daobin Zhou, MD, Andres Sirulnik, MD, PhD, Wanda Ruiz, PhD, Taro Amagasaki, PhD, Kazuo Ito, Koichi Akashi, MD, PhD

Blood (2013) 122 (21): 4086.

https://doi.org/10.1182/blood.V122.21.4086.4086

Published: 2013

Journal Articles

Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 × 10 9 /L and 99 × 10 9 /L

Claire N Harrison, DM FRCP FRCPath, Heinz Gisslinger, MD, Carole B. Miller, MD, Jean-Jacques Kiladjian, MD, PhD, Edric Atienza, MSHS, Viktoriya Stalbovskaya, PhD, Andres Sirulnik, MD, PhD, Haifa Kathrin Al-Ali, MD, Giovanni Barosi, MD, Mary Frances McMullin, MD, Srdan Verstovsek, MD, PhD, Alessandro M. Vannucchi, MD

Blood (2012) 120 (21): 177.

https://doi.org/10.1182/blood.V120.21.177.177

Published: 2012

Journal Articles

The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Mary Frances McMullin, MD, Claire N Harrison, DM FRCP FRCPath, Dietger Niederwieser, Hilde Demuynck, Nadja Jakel, Andres Sirulnik, MD, PhD, Mari McQuity, RN, MPH, Viktoriya Stalbovskaya, PhD, Christian Recher, MD, Koen Theunissen, MD, Heinz Gisslinger, MD, Jean-Jacques Kiladjian, MD, PhD, Haifa-Kathrin Al- Ali

Blood (2012) 120 (21): 2838.

https://doi.org/10.1182/blood.V120.21.2838.2838

Published: 2012

Journal Articles

Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials.

Srdan Verstovsek, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Ruben A. Mesa, Alessandro M. Vannucchi, MD, Jason Gotlib, Giovanni Barosi, MD, Hagop M. Kantarjian, MD, Andres Sirulnik, MD, PhD, Wei Peng, PhD, Victor A. Sandor, MD, CM, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 2847.

https://doi.org/10.1182/blood.V120.21.2847.2847

Published: 2012

Journal Articles

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Francisco Cervantes, MD, Jean-Jacques Kiladjian, MD, PhD, Dietger Niederwieser, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Mari McQuity, RN, MPH, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francesco Passamonti, MD, Tiziano Barbui, MD, Giovanni Barosi, MD, Heinz Gisslinger, MD, Alessandro M. Vannucchi, MD, Laurent Knoops, MD, PhD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 801.

https://doi.org/10.1182/blood.V120.21.801.801

Published: 2012

Journal Articles

Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)

Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Haifa Kathrin Al-Ali, MD, Giovanni Barosi, MD, Claire N Harrison, DM FRCP FRCPath, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Matthew Squires, PhD, Timothy Burn, PhD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, Tiziano Barbui, MD, Heinz Gisslinger, MD, Jean-Jacques Kiladjian, MD, PhD

Blood (2012) 120 (21): 802.

https://doi.org/10.1182/blood.V120.21.802.802

Published: 2012

Journal Articles

Anemia and the Use of Erythropoietic-Stimulating Agents with Ruxolitinib in the COMFORT-II Study

Mary Frances McMullin, MD, Claire N. Harrison, DM, FRCP, FRCPath, Dietger Niederwieser, MD, Hilde Demuynck, MD, PhD, Nadja Jäckel, Andres Sirulnik, MD, PhD, Alison Wearver, PhD, Viktoriya Stalbovskaya, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Haifa Kathrin Al-Ali, MD

Blood (2011) 118 (21): 5147.

https://doi.org/10.1182/blood.V118.21.5147.5147

Published: 2011

Journal Articles

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Eric Qiong Wu, PhD, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Annie Guerin, MSc, Andrew Peng Yu, PhD, Andres Sirulnik, MD, PhD, James D Griffin, MD

Blood (2009) 114 (22): 4270.

https://doi.org/10.1182/blood.V114.22.4270.4270

Published: 2009

Journal Articles

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Steven Grant, MD, Sarah Kolla, Leonardo Andres Sirulnik, MD, PhD, Geoffrey Shapiro, Jeffrey Supko, Brenda Cooper, Edward Perkins, Viswanathan Ramakrishnan, Igor Espinoza-Delgado, MD, M B Tombes, John D Roberts

Blood (2008) 112 (11): 2986.

https://doi.org/10.1182/blood.V112.11.2986.2986

Published: 2008

Journal Articles

The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor

Jotin Marango, Manabu Shimoyama, Hitomi Nishio, Julia A. Meyer, Dong-Joon Min, Andres Sirulnik, Yolanda Martinez-Martinez, Marta Chesi, P. Leif Bergsagel, Ming-Ming Zhou, Samuel Waxman, Boris A. Leibovitch, Martin J. Walsh, Jonathan D. Licht

Blood (2008) 111 (6): 3145–3154.

https://doi.org/10.1182/blood-2007-06-092122

Published: 2008

Journal Articles

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

Daniel J. DeAngelo, MD, PhD, Suzanne Dahlberg, PhD, Lewis B. Silverman, MD, Stephen Couban, MD, Philip C. Amrein, MD, Matthew D. Seftel, MD, A. Robert Turner, MD, Brian Leber, MD, Kang Howsan-Jan, MD, Martha Wadleigh, MD, L. Andres Sirulnik, MD, Jeffrey Supko, PhD, Ilene Galinsky, Stephen E. Sallan, MD, Richard M. Stone, MD

Blood (2007) 110 (11): 587.

https://doi.org/10.1182/blood.V110.11.587.587

Published: 2007

Journal Articles

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

Daniel J. DeAngelo, MD, PhD, Lewis B. Silverman, MD, Stephen Couban, MD, Suzanne Dahlberg, PhD, Philip C. Amrein, MD, Matthew D. Seftel, MD, A. Robert Turner, MD, Martha Wadleigh, MD, L. Andres Sirulnik, MD, PhD, Ilene Galinsky, RN, Stephen E. Sallan, MD, Richard M. Stone, MD

Blood (2006) 108 (11): 1858.

https://doi.org/10.1182/blood.V108.11.1858.1858

Published: 2006

Journal Articles

Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate.

Eyal C. Attar, MD, Daniel J. De Angelo, MD, PhD, Andres Sirulnik, MD, PhD, Martha Wadleigh, MD, Karen K. Ballen, MD, Kenneth B. Miller, MD, Ilene Galinsky, Donna Neuberg, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Richard M. Stone, MD, Philip C. Amrein, MD

Blood (2005) 106 (11): 2782.

https://doi.org/10.1182/blood.V106.11.2782.2782

Published: 2005

Journal Articles

The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor.

Jotin Marango, Manabu Shimoyama, MD, PhD, Boris A. Leibovitch, PhD, Ming Ming Zhou, PhD, Yolanda Martinez, Andres Sirulnik, MD, PhD, Marta Chesi, PhD, P. Leif Bergsagel, MD, Jonathan D. Licht, MD

Blood (2005) 106 (11): 358.

https://doi.org/10.1182/blood.V106.11.358.358

Published: 2005

NARROW

Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis

A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF)

Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 × 10 9 /L and 99 × 10 9 /L

The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials.

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)

Anemia and the Use of Erythropoietic-Stimulating Agents with Ruxolitinib in the COMFORT-II Study

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate.

The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only